4th CML-CAB: Munich, Germany, 18-19 November 2017

On 18-19 November 2017, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, has hosted its fourth meeting to discuss issues of major concern to the CML community.

CML-CAB Members attending the 4th CML-CAB as patient experts:

• Jan Geissler, Germany (co-chair)
• Giora Sharf, Israel (co-chair)
• Jana Pelouchova, Czech Republic
• Mercedes Arteaga, Argentina (representing Latin America) 
• Bahija Gouimi, Morocco (representing Africa and the Middle East) 
• Rita Christensen, Denmark (representing Western Europe)
• Pat Garcia-Gonzalez - The Max Foundation USA (representing Latin America) 
• Rod Padua, Philippines (representing East Asia and Pacific)  
• Felice Bombaci, Italy (Western Europe) 
• Ferdinand Micho, Kenya (Africa) 
• Silvia Castillo De Armas, Guatemala (Latin America) 
• Šarūnas Narbutas, Lithuania (Eastern Europe) 
• Lisa Machado, Canada (North America) 
• Cornelia Borowczak, Germany

Plus, the CML Advocates Network team Lidija Pecova and Celia Marín.

CML-CAB with Incyte & Takeda, 18th November 2017, 13:00-17:00

The following topics were discussed during the CML-CAB:

• Clinical Update on Ponatinib
• Discussion of The Lifecycle Plan for Ponatinib
• Access Issues
• Involvement of the CML Community in Research & Development (R&D)
• Dialogue and Next Steps

Non-confidential minutes of the meeting will be available to CML Advocates Network members soon. 

CML-CAB with Novartis, 19th November, 08:00-16:00

The following topics were discussed during the CML-CAB:

• Clinical Development of ABL001 and Nilotinib 
• Collaboration Between Novartis and CML Community in CML Drug Development 
• Therapy-Free Remission 
• Follow-up Actions and Next Steps

Non-confidential minutes of the meeting will be available to CML Advocates Network members soon.